OOIR: Observatory of International Research

Papers

(The TQCC of Biopharmaceutics & Drug disPosition is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)

Article	Citations
Physiological‐based pharmacokinetic modeling trends in pharmaceutical drug development over the last 20‐years; in‐depth analysis of applications, organizations, and platforms	69
Polymeric nanoencapsulation of zaleplon into PLGA nanoparticles for enhanced pharmacokinetics and pharmacological activity	25
Physiologically‐based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment	14
Effects of gut microbiota on in vivo metabolism and tissue accumulation of cytochrome P450 3A metabolized drug: Midazolam	14
Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help	11
Interspecies prediction of pharmacokinetics and tissue distribution of doxorubicin by physiologically‐based pharmacokinetic modeling	10
Concomitant lansoprazole ameliorates cisplatin‐induced nephrotoxicity by inhibiting renal organic cation transporter 2 in rats	10
In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies	10
Preliminary physiologically based pharmacokinetic modeling of renally cleared drugs in Chinese pregnant women	10
Biodistribution and delivery of oligonucleotide therapeutics to the central nervous system: Advances, challenges, and future perspectives	9
Inhibition of human UDP‐glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug–drug interactions	9
Across‐species meta‐analysis of dexamethasone pharmacokinetics utilizing allometric and scaling modeling approaches	9
Comparative in silico prediction of P‐glycoprotein‐mediated transport for 2010–2020 US FDA‐approved drugs using six Web‐tools	8
Favipiravir biotransformation in liver cytosol: Species and sex differences in humans, monkeys, rats, and mice	8
When special populations intersect with drug–drug interactions: Application of physiologically‐based pharmacokinetic modeling in pregnant populations	8
Self‐emulsifying drug delivery system of (R)‐α‐lipoic acid to improve its stability and oral absorption	7
Effects of low temperature on blood‐to‐plasma ratio measurement	7
Characterization of red ginseng–drug interaction by CYP3A activity increased in high dose administration in mice	7
Impact of age, hypercholesterolemia, and the vitamin D receptor on brain endogenous β‐amyloid peptide accumulation in mice	6
Switchability and minimal effect of food on pharmacokinetics of modified release tablet strengths of omecamtiv mecarbil, a cardiac myosin activator	6
The role of the efflux transporter, P‐glycoprotein, at the blood–brain barrier in drug discovery	6
The application of precision dosing in the use of sertraline throughout pregnancy for poor and ultrarapid metabolizer CYP 2C19 subjects: A virtual clinical trial pharmacokinetics study	6
Recent advances in the in vitro and in vivo methods to assess impact of P‐glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition	5
Physiologically based pharmacokinetic modelling of acetaminophen in preterm neonates—The impact of metabolising enzyme ontogeny and reduced cardiac output	5
Mechanistic evaluation of the effect of sodium‐dependent glucose transporter 2 inhibitors on delayed glucose absorption in patients with type 2 diabetes mellitus using a quantitative systems pharmacol	5

Blood retinal barrier and ocular pharmacokinetics: Considerations for the development of oncology drugs	5
Non‐clinical characterization of the disposition of EMA401, a novel small molecule angiotensin II type 2 receptor (AT2R) antagonist	5
In‐depth analysis of patterns in selection of different physiologically‐based pharmacokinetic modeling tools: Part II — Assessment of model reusability and comparison between open and non‐open source‐	4
In vitro and in silico interactions of antiulcer, glucocorticoids and urological drugs on human carbonic anhydrase I and II isozymes	4
Metabolism, pharmacokinetics, and anticonvulsant activity of a deuterated analog of the α2/3‐selective GABAkine KRM‐II‐81	4
Stable solid dispersion of lurasidone hydrochloride with augmented physicochemical properties for the treatment of schizophrenia and bipolar disorder	4
In vivo monitoring of brain pharmacokinetics and pharmacodynamics with cerebral open flow microperfusion	4
Prediction of a clinically effective dose of THY1773, a novel V_1Breceptor antagonist, based on preclinical data	4
Physiologically based pharmacokinetic model of renally cleared antibacterial drugs in Chinese renal impairment patients	4
Simulation of febuxostat pharmacokinetics in healthy subjects and patients with impaired kidney function using physiologically based pharmacokinetic modeling	4
In‐depth analysis of patterns in selection of different physiologically based pharmacokinetic modeling tools: Part I – Applications and rationale behind the use of open source‐code software	4
Comparison of tissue pharmacokinetics of esflurbiprofen plaster with flurbiprofen tablets in patients with knee osteoarthritis: A multicenter randomized controlled trial	4
Lisdexamfetamine and amphetamine pharmacokinetics in oral fluid, plasma, and urine after controlled oral administration of lisdexamfetamine	3
Predicting transporter mediated drug–drug interactions via static and dynamic physiologically based pharmacokinetic modeling: A comprehensive insight on where we are now and the way forward	3
Model‐informed drug development: The mechanistic HSK3486 physiologically based pharmacokinetic model informing dose decisions in clinical trials of specific populations	3
Effect of hepar‐protecting Wuzhi capsule on pharmacokinetics and dose‐effect character of tacrolimus in healthy volunteers	3
Changes in uridine 5′‐diphospho‐glucuronosyltransferase 1A6 expression by histone deacetylase inhibitor valproic acid	3
Population pharmacokinetics of tacrolimus in Chinese adult liver transplant patients	3
Effects of aged garlic and ginkgo biloba extracts on the pharmacokinetics of sofosbuvir in rats	3
Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure	3
Fluorouracil uptake in triple‐negative breast cancer cells: Negligible contribution of equilibrative nucleoside transporters 1 and 2	3
Physiologically based pharmacokinetic model to predict drug concentrations of breast cancer resistance protein substrates in milk	3
Cytochrome P450 expression patterns in human osteoblasts during osteogenic differentiation with or without TNFα treatment	3
Absorption, tissue disposition, and excretion of fasudil hydrochloride, a RHO kinase inhibitor, in rats and dogs	3
Absorption, metabolism, and pharmacokinetic profile of xanthohumol in rats as determined via UPLC‐MS/MS	3
In vitro and ex vivo experimental models for evaluation of intranasal systemic drug delivery as well as direct nose‐to‐brain drug delivery	3